SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike rallied with cybersecurity peers as reports of critical PHP vulnerabilities and related service disruptions heightened concern about AI-enabled cyber threats and demand for protection. Traders welcomed the sectors strength, while skeptics argued the move may be hype given the stocks stretched valuation.

Cash Cat

CASHCAT is drawing attention for its sharp, volatile swings after a major rally and steep pullbacks, with traders debating whether dips are buying opportunities or signs of a pump-and-dump. Bulls point to its Robinhood-chain and meme-coin ecosystem narrative, while skeptics question its utility and warn of further losses; claims of manipulation and short squeezes remain speculation.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillars sharp pullback ahead of its quarterly report is driving debate, despite traders pointing to a record backlog and data-center power demand. Some see an oversold buying opportunity, while others expect further weakness if results or guidance fail to meet high expectations.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced 2026 outlook, and suspended dividend to prioritize debt reduction have driven heavy selling; management attributed the slump to recession-level appliance demand and the Iran war. Traders are debating whether the decline reflects a temporary demand shock or deeper problems with the companys debt, execution, and management, while some see the selloff as a contrarian buying opportunity.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is under pressure as investors question whether Auvelitys launch for Alzheimers-related agitation is gaining traction, with prescription data and sales-force execution under scrutiny ahead of the Q3 results. Traders disagree on whether reported scripts undercount demand from samples and long-term-care facilities or point to a slower-than-expected ramp, while managements silence has added to uncertainty.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Toshibas plan to expand hard-drive capacity has raised fears that added competition could weaken Seagates pricing power, prompting sharp swings in STX alongside Western Digital. Traders are divided: some see a lasting threat to the storage-scarcity thesis, while others view the selloff as an overreaction given the long ramp-up and strong AI data-center demand.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins sharp pullback below the widely watched $80,000 level and reports of leveraged long liquidations are driving attention, with traders debating whether the decline signals a deeper correction or a low-volume shakeout. Bearish calls for further losses compete with dip-buying and expectations of a rebound.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Attention centers on Coinbases Q3 report: traders are focused on several quarters of declining revenue and whether results can show a turnaround, while bulls anticipate a rebound and bears worry about another weak report. The debate is amplified by crypto-market volatility and complaints that COIN has lagged Bitcoin on rallies while falling alongside it during selloffs.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Attention centers on Teladocs upcoming quarterly results and whether its BetterHelp shift from cash-pay to insurance can stabilize the business after weaker guidance. Bulls point to a possible rebound and heavily shorted shares, while bears question managements execution and expect continued business weakness.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

ARKK is drawing attention as traders debate whether its attempt to break out of a prolonged growth-stock slump can hold. Bulls point to improving technicals and renewed interest in high-beta names, while skeptics cite the funds history of underperformance and question Cathie Woods portfolio decisions.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data  

Equity

MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in certain patients with active psoriatic arthritis. 


MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data

A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.


MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event

Some Stocktwits users voiced optimism for the inflammation-drug maker getting acquired by pharma giant Merck. 

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations

BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.

Why Did MLTX Stock Jump 45% In Pre-Market Today?

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

iShares Trust - iShares ESG Aware MSCI USA Small-Cap ETF

Neutral Sentiment

<ul class="summary-bullets"><li>During its Investor Day on June 22, management stated that the company’s largest trial to date “will read in about a month’s time.”</li><li>MoonLkae has two additional catalysts slated for the remainder of the year.&nbsp;</li><li>The company plans to submit an application to the U.S. Food and Drug Administration seeking approval for sonelokimab in hidradenitis suppurativa at the end of September 2026.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) traded 5% lower on Monday as traders await the results of a key clinical trial of the company’s sonelokimab in certain patients with active psoriatic arthritis (PsA).MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in patients with active psoriatic arthritis (PsA) who have not been treated with a specific class of therapy called biologics. More specifically, during its Investor Day on June 22, management stated that the company’s largest trial to date “will read in about a month’s time.”That commentary pointed to a late-July or early-August 2026 announcement window. As of Monday, the data has not yet been released. Investors continue to debate whether the results will arrive as a standalone press release or potentially be timed alongside the company’s upcoming Q2 2026 financial results.IZAR-1 is a large late-stage trial testing MoonLake’s drug sonelokimab in about 960 adults with psoriatic arthritis. Psoriatic arthritis (PsA) is a long-term condition that affects some people who have (or have had) psoriasis — the skin disease that produces red, scaly patches. In PsA, the immune system mistakenly attacks the joints and the places where tendons and ligaments attach to bone, leading to pain, stiffness, and swelling.Patients in the IZAR-1 trial are randomly given either the real drug or a placebo, and neither they nor their doctors know which one they received. The main goal is to prove the drug works better than the placebo at meaningfully improving joint symptoms after 16 weeks. The trial also checks other benefits, such as clearer skin, overall better disease control, and how patients feel in daily life.<h2 class="st-heading-2">Other Near-Term Catalysts For MLTX</h2>Beyond IZAR-1, MoonLake’s pipeline and regulatory calendar remain busy through the rest of 2026.The company plans to submit an application to the U.S. Food and Drug Administration seeking approval for sonelokimab in hidradenitis suppurativa, a chronic, painful inflammatory skin disease, at the end of September 2026. Acceptance and a potential Priority Review decision are expected by the end of November 2026, with a possible U.S. launch targeted for the second half of 2027 if approved.Another late-stage trial in PsA patients who did not respond well to an older class of drugs is expected to report its main results in the second half of 2026.MoonLake raised roughly $200 million in a public offering in late June, strengthening its cash position to fund these steps.<h2 class="st-heading-2">How Did MLTX Retail Traders React?</h2>On Stocktwits, retail sentiment around MLTX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user voiced optimism for trial success with IZAR-1, citing strong mid-stage trial outcomes.<stembedurl>https://www.stocktwits.com/Doxtator/message/660675293</stembedurl>Another expects the company to announce the trial outcome by mid-August, urging others to “hold.”<stembedurl>https://www.stocktwits.com/TheSuper/message/660698199</stembedurl><a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> has gained nearly 33% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/northrop-grumman-to-boost-missile-component-production-for-arsenal-of-freedom-retail-views-steady-execution-to-be-key-for-growth/cZoTS9dRJ32">Northrop Grumman To Boost Missile Component Production For ‘Arsenal of Freedom’ – Retail Views Steady Execution To Be Key For Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

During its Investor Day on June 22, management stated that the company’s largest trial to date “will read in about a month’s time.”MoonLkae has two additional catalysts slated for the remainder of the year. The company plans to submit an application to th

iShares ESG Aware MSCI USA Small-Cap ETF

MoonLake Immunotherapeutics

Vanguard Health Care ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

ESML iShares ESG Aware MSCI USA Small-Cap ETF

Fundamentals

Latest ESML News